Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2006-12-19
2008-08-26
Helms, Larry R. (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S137100
Reexamination Certificate
active
07416725
ABSTRACT:
The present invention provides compositions that enhance or inhibit the interactions of galectin-8 and galectin-8-like proteins with other extracellular matrix proteins or cell surface receptors, and methods for the use thereof as physiological modulators of cell adhesion and in treatment of tumors, both in vivo or ex vivo. It further provides compositions and methods for modulating the expression of galectin-8, and galectin-8-like proteins, particularly to novel antisense oligonucleotides.
REFERENCES:
patent: 3687808 (1972-08-01), Merigan et al.
patent: 4469863 (1984-09-01), Ts'o et al.
patent: 4667025 (1987-05-01), Miyoshi et al.
patent: 4762779 (1988-08-01), Snitman
patent: 5034506 (1991-07-01), Summerton et al.
patent: 5278302 (1994-01-01), Caruthers et al.
patent: 5489677 (1996-02-01), Sanghvi et al.
patent: 5525465 (1996-06-01), Haralambidis et al.
patent: 5539082 (1996-07-01), Nielsen et al.
patent: 5587361 (1996-12-01), Cook et al.
patent: 5596091 (1997-01-01), Switzer
patent: 5597909 (1997-01-01), Urdea et al.
patent: 5614617 (1997-03-01), Cook et al.
patent: 5618704 (1997-04-01), Sanghvi et al.
patent: 5627053 (1997-05-01), Usman et al.
patent: 5670633 (1997-09-01), Cook et al.
patent: 5677439 (1997-10-01), Weis et al.
patent: 5681941 (1997-10-01), Cook et al.
patent: 5688941 (1997-11-01), Cook et al.
patent: 5714331 (1998-02-01), Buchardt et al.
patent: 5719262 (1998-02-01), Buchardt et al.
patent: 5869289 (1999-02-01), Hawkins et al.
patent: 5908761 (1999-06-01), Zick
patent: 6228642 (2001-05-01), Baker et al.
patent: 6281333 (2001-08-01), Hawkins et al.
patent: WO 99/43857 (1999-09-01), None
Levy et al. Journal of Biological Chemistry, vol. 276, No. 33, pp. 31285-31295, published May 22, 2001.
Barondes et al., Structures and function of a large family of animal lectins,The Journal of Biological Chemistry, 269(33)20807-20810 (1994).
Berge et al., Pharmaceutical salts,Journal of Pharmaceutical Sciences, 66(1)1-19 (1977).
Camby et al., Galectins are differentially expressed in supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas, and significantly modulate tumor astrocytes migration,Brain Pathology, 11:12-26 (2001).
Chonn et al., Recent advances in liposomal drug-delivery systems,Current Opinion in Biotechnology, 6:698-708 (1995).
Englisch et al., Chemically modified oligonucleotides as probes and inhibitors,Angew. Chem. Int. Ed. Engl., 30:613-629 (1991).
Eshhar, Zeilig, Monolonal Antibody Strategy and Techniques.,hybridoma in biotechnology and medicine, Springer, T. ed., Plenum Press. Chapter 1, pp. 1-41. (1985).
Giancotti et al., Integrin signaling,Science, 285:10281032 (1999).
Hadari et al., Galectin-8 binding to integrins inhibits cell adhesion and induces apoptosis,Journal of Cell Science, 113:2385-2397 (2000).
Hadari et al., Galectin-8: A new rat lectin, related to galectin-4,The Journal of Biological Chemistry, 270(7)3447-3453 (1995).
Hirabayashi et al., Effect of amino acid substitution by site-directed mutagenesis on the carbohydrate recognition and stability of human 14-k-Da β-galactoside-binding lectin,The Journal of Biological Chemistry, 266(35)23648-23653 (1991).
Hynes, Cell adhesion: old and new questions,Trends Cell Biol, 9:M33-M37 (1999).
Jui et al., Characterization of a hybrid receptor formed by dimerization of the insulin receptor-related receptor (IRR) with the insulin receptor (IR): coexpression of cDNAs encoding human IRR and human IR in NIH-3T3 cells,Biochemistry, 35:14326-14330 (1996).
Klapper et al., A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors,Oncogene, 14:2099-2109 (1997).
Kroschwitz, J I ed. John Wiley & Sons, Polypeptides,Concise Encyclopedia of polymer science and engineering, 858-859 (1990).
Levy et al., Galectin-8 functions an a matricellular modulator of cell adhesion,The Journal of Biological Chemistry, 276(33)31285-31295 (2001).
Madsen et al., Cloning, expression, and chromosome mapping of human galectin-7,The Journal of Biological Chemistry, 270(11)5823-5829 (1996).
Martin, Ein neuer Zugang zu 2′-O-alkylribonuclosiden und Eigenschaften deren oligonucleotide,Helvetica Chimica Acta, 78:486-504 (1995).
Nagy et al., Galectin-8 expression decreases in cancer compared with normal and dysplastic human colon tissue and acts significantly on human colon cancer cell migration as a suppressor,Gat, 50:392-401 (2002).
Neugebauer et al., Cell-surface regulation of β1-integrin activity on developing retinal neurons,Nature, 350:68-71 (1991).
Nielsen et al., Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide,Science, 254(5037)1497-1500 (1991).
Paz et al., Phosphorylation of insulin receptor substrate-1 (IRS-1) by protein kinase B positively regulates IRS-1 function,The Journal of Biological Chemistry, 274(40)28816-28822 (1999).
Raz et al, Differential expression of endogenous lectins on the surface of nontumorigenic, tumorigenic, and metastatic cells,Cancer Res, 46:3667-3672 (1986).
Raz et al., Evidence for the role of 34-kDa galactoside-binding lectin in transformation and metastasis,Int. J. Cancer, 46:871-877 (1990).
Sanghvi, et al.,Antisense Research and Applications, CRC Press, Boca Raton. Chapter 15: 276-278. (1993).
Sanghvi, et al.,Antisense Research and Applications, CRC Press, Boca Raton. Chapter 16: 289-302. (1993.
Sharon et al., Lectins-proteins with a sweet tooth: functions in cell recognition,Essays Biochem., 30:59-75 (1995).
Su, Zao-Zhong et al., Surface-epitope masking and expression cloning identifies the human prostate carcinoma tumor antigen gene PCTA-1 a member of the galectin gene family,Proc. Natl. Acad. Sci. USA, 93:7252-7257 (1996).
Tracey et al., Subunit molecular mass assignment of 14,654 Da to the soluble β-galactoside-binding lectin from bovine heart muscle and demonstration of intramolecular disulfide bonding associated with oxidative inactivation,The Journal of Biological Chemistry, 267(15)10342-10347 (1992).
Andrew Chin, On the preparation and utilization of isolated and purified oligonucleotides, deposited at the Kathrine R. Evern Law Library of the University of North Carolina on Mar. 11, 2002 on CD-ROM.
Jui et al., Characterization of a hybrid receptor formed by dimerization of the insulin receptor-related receptor (IRR) with the insulin receptor (IR): coexpression of cDNAs encoding human IRR and human IR in NIH-3T3 cells,Biochemistry, 35:14326-14330 (1996), U.S. Appl. No. 11/612,910.
Levy, Y., et al.J. Biol. Chem., vol. 276, No. 33, pp. 31, 285-31, 295 (2001).
R. I. Freshney, Culture of Animal Cells, A Manual of Basic Technique, pp. 3-4 (Alan R. Liss, New York, Publ., 1983).
G. B. Dermer, Bio/Technology, Vo. 12, p. 320 (1994).
Levy, R. Et al.,J. Biol. Chem., vol. 276, No. 33, pp. 31, 285-31, 295 (2001).
Hadari, Y. R. et al.,J. Cell. Science, vol. 113, pp. 2385-2397 (2000).
Arbel-Goren Rinat
Hadari Yaron R.
Levy Yifat
Ronen Denise
Zick Yehiel
Browdy and Neimark PLLC
Helms Larry R.
Natarajan Meera
Yeda Research and Development Co. Ltd.
LandOfFree
Compositions and methods of using galectin-8 as an inhibitor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods of using galectin-8 as an inhibitor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods of using galectin-8 as an inhibitor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4010972